Sorrento Therapeutics (NASDAQ: SRNE) and Medpace (NASDAQ:MEDP) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.
Earnings & Valuation
This table compares Sorrento Therapeutics and Medpace’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Sorrento Therapeutics||$151.85 million||3.24||$9.13 million||($1.14)||-4.74|
|Medpace||$436.15 million||2.94||$39.12 million||$1.52||23.80|
This table compares Sorrento Therapeutics and Medpace’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional and Insider Ownership
11.6% of Sorrento Therapeutics shares are owned by institutional investors. Comparatively, 23.6% of Medpace shares are owned by institutional investors. 5.0% of Sorrento Therapeutics shares are owned by insiders. Comparatively, 25.8% of Medpace shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Volatility and Risk
Sorrento Therapeutics has a beta of 2.43, meaning that its share price is 143% more volatile than the S&P 500. Comparatively, Medpace has a beta of 0.11, meaning that its share price is 89% less volatile than the S&P 500.
This is a breakdown of current ratings for Sorrento Therapeutics and Medpace, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Sorrento Therapeutics currently has a consensus price target of $17.00, indicating a potential upside of 214.81%. Medpace has a consensus price target of $36.75, indicating a potential upside of 1.58%. Given Sorrento Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Sorrento Therapeutics is more favorable than Medpace.
Sorrento Therapeutics beats Medpace on 8 of the 14 factors compared between the two stocks.
About Sorrento Therapeutics
Sorrento Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, acquisition, development and commercialization of drug therapeutics. Its primary therapeutic focus is oncology, including the treatment of chronic cancer pain. It is also developing therapeutic products for other indications, including immunology and infectious diseases. Its products in the pipeline include Chimeric Antigen Receptor-T Cell (CAR-T) programs, resiniferatoxin (RTX), and biosimilar/biobetter antibodies clinical development programs. Its pipeline also includes preclinical fully human therapeutic monoclonal antibodies (mAbs), including biosimilars/biobetters, fully human anti-PD-L1 and anti-PD-1 checkpoint inhibitors derived from its G-MAB library platform, antibody drug conjugates (ADCs), bispecific antibodies (BsAbs), as well as CAR-T and Chimeric Antigen Receptor Natural Killer (NK) cells (CAR. NK) for adoptive cellular immunotherapy.
Medpace Holdings, Inc. is a clinical contract research organization. The Company provides clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.
Receive News & Ratings for Sorrento Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sorrento Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.